Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-312023-01-01falseNBS Scientific Ltd is a distribution company in the United Kingdom. NBS Scientific supply products to customers to help improve their sample collection, sample storage, sample tracking, lab automation, and in vitro gastrointestinal research processes. NBS Scientific also provide a wide range of technical services to ensure their equipment functions properly every day of the year.33falsetruefalse 11207745 2023-01-01 2023-12-31 11207745 2022-01-01 2022-12-31 11207745 2023-12-31 11207745 2022-12-31 11207745 c:Director1 2023-01-01 2023-12-31 11207745 d:MotorVehicles 2023-01-01 2023-12-31 11207745 d:MotorVehicles 2023-12-31 11207745 d:MotorVehicles 2022-12-31 11207745 d:MotorVehicles d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 11207745 d:OfficeEquipment 2023-01-01 2023-12-31 11207745 d:OfficeEquipment 2023-12-31 11207745 d:OfficeEquipment 2022-12-31 11207745 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 11207745 d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 11207745 d:CurrentFinancialInstruments 2023-12-31 11207745 d:CurrentFinancialInstruments 2022-12-31 11207745 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 11207745 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 11207745 d:ShareCapital 2023-12-31 11207745 d:ShareCapital 2022-12-31 11207745 d:RetainedEarningsAccumulatedLosses 2023-12-31 11207745 d:RetainedEarningsAccumulatedLosses 2022-12-31 11207745 c:OrdinaryShareClass1 2023-01-01 2023-12-31 11207745 c:OrdinaryShareClass1 2023-12-31 11207745 c:OrdinaryShareClass1 2022-12-31 11207745 c:FRS102 2023-01-01 2023-12-31 11207745 c:Audited 2023-01-01 2023-12-31 11207745 c:FullAccounts 2023-01-01 2023-12-31 11207745 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 11207745 c:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 11207745 e:PoundSterling 2023-01-01 2023-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 11207745









NBS SCIENTIFIC LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2023

 
NBS SCIENTIFIC LIMITED
REGISTERED NUMBER: 11207745

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
18,516
-

  
18,516
-

Current assets
  

Debtors: amounts falling due within one year
 5 
381,876
342,852

Cash at bank and in hand
  
44,130
35,818

  
426,006
378,670

Creditors: amounts falling due within one year
 6 
(68,425)
(41,690)

Net current assets
  
 
 
357,581
 
 
336,980

Total assets less current liabilities
  
376,097
336,980

  

Net assets
  
376,097
336,980


Capital and reserves
  

Called up share capital 
 7 
1
1

Profit and loss account
  
376,096
336,979

  
376,097
336,980


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




M V D Luitgaren
Director

Date: 19 September 2024

The notes on pages 2 to 7 form part of these financial statements.

Page 1

 
NBS SCIENTIFIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

NBS Scientific Limited (“NBS UK”) is a UK subsidiary of NBS Scientific Holding B.V. and acts as a distribution agent for the Dutch company. NBS UK distributes pharmaceutical goods.
The Company is limited by shares and is incorporated in the United Kingdom.  
The address of its registered office is International House, Southampton International Business Park, Southampton, Hampshire, England, SO18 2RZ

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on the going concern basis as in the opinion of the directors the company will generate future income sufficent to cover the liabilities of the company.
The company has made a profit in the year and relies on the support of a group entity which has confirmed its intention to provide support for a period of twelve-months from the date of signing of the accounts

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

NBS Scientific Ltd sells products from the NBS Scientific product portfolio to end customers in the United Kingdom. The products are sold in the name and for the risk of NBS Scientific Holding BV. For this effort NBS Scientific Ltd. charges a fee to NBS Scientific Holding BV. This fee is determined based on a percentage 18% of the Net Sales invoiced by NBS Scientific Holding BV to end customers in the United Kingdom.

 
2.4

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Page 2

 
NBS SCIENTIFIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.5

Pensions

Defined contribution pension plan
The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.
The contributions are recognised as an expense in the Statement of Comprehensive Income when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.6

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 3

 
NBS SCIENTIFIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.7
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
25%
Office equipment
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 4

 
NBS SCIENTIFIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.8

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans to related parties.
(i) Financial assets
Basic financial assets, including trade and other debtors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.
 
Such assets are subsequently carried at amortised cost using the effective interest method. At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in the Statement of Income and Retained Earnings.
Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.
(ii) Financial liabilities
Basic financial liabilities, including trade and other creditors and amounts owed to group undertaking, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.
(iii) Offsetting
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.


3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2022 - 3).

Page 5

 
NBS SCIENTIFIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


Tangible fixed assets





Motor vehicles
Plant and machinery
Total

£
£
£



Cost


At 1 January 2023
-
1,809
1,809


Additions
44,349
-
44,349


Disposals
(24,599)
-
(24,599)



At 31 December 2023

19,750
1,809
21,559



Depreciation


At 1 January 2023
-
1,809
1,809


Charge for the year on owned assets
5,078
-
5,078


Disposals
(3,844)
-
(3,844)



At 31 December 2023

1,234
1,809
3,043



Net book value



At 31 December 2023
18,516
-
18,516



At 31 December 2022
-
-
-


5.


Debtors

2023
2022
£
£


Trade debtors
362,692
314,879

Other debtors
10,948
21,732

Prepayments and accrued income
8,236
6,241

381,876
342,852


Page 6

 
NBS SCIENTIFIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
7,524
2,908

Amounts owed to group undertakings
9,850
12,531

Corporation tax
34,783
22,489

Other creditors
518
262

Accruals and deferred income
15,750
3,500

68,425
41,690



7.


Share capital

2023
2022
£
£
Authorised, allotted, called up and fully paid



100 (2022 - 100) Ordinary shares of £0.01 each
1
1



8.


Related party transactions

The Company has taken advantage of the exemption conferred by FRS 102 section 33.1A from the requirement to disclose transaction with other wholly owned group undertakings.


9.


Controlling party

The Company is a wholly owned subsidiary of NBS Scientific Holding B.V, a company registered in Netherlands.
The Registered Office and principal place of business of NBS Scientific Holding B.V. is Meerpaalweg 6, 1332 Bb, Almere, Netherlands
The ultimate parent is Tracee Management B. V, a company registered in Netherlands. 
The Registered Office and principal place of business of Tracee Management B.V is Meerpaalweg 6, 1332 Bb, Almere, Netherlands


10.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2023 was unqualified.

The audit report was signed on 19 September 2024 by Nick Bishop FCA (Senior Statutory Auditor) on behalf of BKL Audit LLP.

 
Page 7